Modality
mRNA
MOA
SOS1i
Target
Menin
Pathway
Angiogenesis
MyelofibrosisIPFEoE
Development Pipeline
Preclinical
~Mar 2023
→ ~Jun 2024
Phase 1
Sep 2024
→ Mar 2030
Phase 1Current
NCT06361651
1,519 pts·IPF
2025-06→2025-02·Active
NCT05491992
33 pts·IPF
2024-09→2030-03·Completed
1,552 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-02-181.1y agoInterim· IPF
2030-03-144.0y awayInterim· IPF
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Complet…
P1
Active
Catalysts
Interim
2025-02-18 · 1.1y ago
IPF
Interim
2030-03-14 · 4.0y away
IPF
ActiveCompleted|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin |